350 related articles for article (PubMed ID: 10802002)
1. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy.
Ramires FJ; Mansur A; Coelho O; Maranhão M; Gruppi CJ; Mady C; Ramires JA
Am J Cardiol; 2000 May; 85(10):1207-11. PubMed ID: 10802002
[TBL] [Abstract][Full Text] [Related]
2. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
[TBL] [Abstract][Full Text] [Related]
3. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy.
Meinertz T; Hofmann T; Kasper W; Treese N; Bechtold H; Stienen U; Pop T; Leitner ER; Andresen D; Meyer J
Am J Cardiol; 1984 Mar; 53(7):902-7. PubMed ID: 6702645
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Zeng XH; Zeng XJ; Li YY
Am J Cardiol; 2003 Jul; 92(2):173-6. PubMed ID: 12860219
[TBL] [Abstract][Full Text] [Related]
5. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease.
Barr CS; Lang CC; Hanson J; Arnott M; Kennedy N; Struthers AD
Am J Cardiol; 1995 Dec; 76(17):1259-65. PubMed ID: 7503007
[TBL] [Abstract][Full Text] [Related]
6. Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship.
Zannad F; Dousset B; Alla F
Hypertension; 2001 Nov; 38(5):1227-32. PubMed ID: 11711528
[TBL] [Abstract][Full Text] [Related]
7. Spironolactone in congestive heart failure.
Soberman JE; Weber KT
Curr Hypertens Rep; 2000 Oct; 2(5):451-6. PubMed ID: 10995520
[TBL] [Abstract][Full Text] [Related]
8. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
Fügedi K
Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
[TBL] [Abstract][Full Text] [Related]
9. Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
Esposito CT; Varahan S; Jeyaraj D; Lu Y; Stambler BS
J Cardiovasc Electrophysiol; 2013 Jul; 24(7):806-12. PubMed ID: 23489714
[TBL] [Abstract][Full Text] [Related]
10. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
Brilla CG; Schencking M; Scheer C; Rupp H
Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
[TBL] [Abstract][Full Text] [Related]
11. [Arrhythmia risk stratification in patients with heart failure according to drug treatment and its effects].
Gronda E; Mangiavacchi M; Andreuzzi B; Municinò A
Ital Heart J Suppl; 2001 Dec; 2(12):1278-83. PubMed ID: 11838348
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance and management of arrhythmias in the heart failure patient.
Greene HL
Clin Cardiol; 1992 Sep; 15 Suppl 1():I13-21. PubMed ID: 1395210
[TBL] [Abstract][Full Text] [Related]
13. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure.
Gao X; Peng L; Adhikari CM; Lin J; Zuo Z
J Card Fail; 2007 Apr; 13(3):170-7. PubMed ID: 17448413
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of nonsustained ventricular tachycardia in severe congestive heart failure.
Maskin CS; Siskind SJ; LeJemtel TH
Am Heart J; 1984 May; 107(5 Pt 1):896-901. PubMed ID: 6720519
[TBL] [Abstract][Full Text] [Related]
15. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
Kasama S; Toyama T; Sumino H; Kumakura H; Takayama Y; Minami K; Ichikawa S; Matsumoto N; Sato Y; Kurabayashi M
Int J Cardiol; 2013 Jul; 167(1):244-9. PubMed ID: 22245478
[TBL] [Abstract][Full Text] [Related]
16. Aldosterone antagonists in hypertension and heart failure.
Mantero F; Lucarelli G
Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
[TBL] [Abstract][Full Text] [Related]
17. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
Svensson M; Gustafsson F; Galatius S; Hildebrandt PR; Atar D
J Card Fail; 2004 Aug; 10(4):297-303. PubMed ID: 15309695
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and long-term prognosis in patients with chronic heart failure and reduced ejection fraction in China.
Liu X; Yu H; Pei J; Chu J; Pu J; Zhang S
Heart Lung Circ; 2014 Sep; 23(9):818-26. PubMed ID: 24881031
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
Stier CT; Koenig S; Lee DY; Chawla M; Frishman WH
Heart Dis; 2003; 5(2):102-18. PubMed ID: 12713678
[TBL] [Abstract][Full Text] [Related]
20. [Spontaneous and stimulus-induced arrhythmia behavior in dilated cardiomyopathy].
Gonska BD; Bethge KP; Kreuzer H
Z Kardiol; 1987 Sep; 76(9):546-53. PubMed ID: 2447707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
